Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

May 9 2022Regulatory
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

Abstract supports ongoing Phase 3 program and planned NDA submission LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of an abstract

May 4 2022Regulatory
Verona Pharma Announces May 2022 Investor Conference Participation

LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: LifeSci Partners Virtual Immunology & Inflammation Symposium Date: Tuesday, May 10 Time: 9:00 AM ET / 2:00

May 3 2022Regulatory
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the

April 19 2022Regulatory
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2022 on Tuesday, May

March 14 2022Regulatory
James Brady Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Director. Mr.

March 3 2022Regulatory
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2022. All rights reserved